Confronto
DSIP vs. Icatibant
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
62568-57-4
138614-30-9
Peso molecolare
848.81 g/mol
1304.52 g/mol
Emivita
0.1 h
nessun dato
Sequenza
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glunessun dato
Meccanismo d'azione
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Icatibant
Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.
Base di evidenze
Evidenza più alta
Studio sull'uomo
RCT sull'uomo
Studi
4
1
di cui sull'uomo
1
1
Effetti registrati
3
1
Contraddizioni aperte
1
0
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between DSIP and Icatibant?
- DSIP is classified as "Ricerca (altro)", while Icatibant is classified as "Ricerca (altro)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Icatibant?
- The highest available evidence level is "Studio sull'uomo" for DSIP and "RCT sull'uomo" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Icatibant in Germany and the United States?
- Germania: DSIP — Non approvato, Icatibant — Su prescrizione. Stati Uniti: DSIP — Non approvato, Icatibant — Su prescrizione. These are factual summaries with source and review date on the individual pages.